Literature DB >> 20096010

Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells.

Andrew J Campbell1, Linden Lyne, Philip J Brown, Rosalind J Launchbury, Paola Bignone, Jianxiang Chi, Giovanna Roncador, Charles H Lawrie, Kevin C Gatter, Rajko Kusec, Alison H Banham.   

Abstract

FOXP2 mutation causes a severe inherited speech and language defect, while the related transcription factors FOXP1, FOXP3 and FOXP4 are implicated in cancer. FOXP2 mRNA and protein expression were characterised in normal human tissues, haematological cell lines and multiple myeloma (MM) patients' samples. FOXP2 mRNA and protein were absent in mononuclear cells from different anatomical sites, lineages and stages of differentiation. However, FOXP2 mRNA and protein was detected in several lymphoma (8/20) and all MM-derived cell lines (n = 4). FOXP2 mRNA was expressed in bone marrow samples from 96% of MM patients (24/25), 66.7% of patients with the pre-neoplastic plasma cell proliferation monoclonal gammopathy of undetermined significance (MGUS) (6/9), but not in reactive plasma cells. The frequency of FOXP2 protein expression in CD138(+) plasma cells was significantly higher in MGUS (P = 0.0005; mean 46.4%) and MM patients (P < or = 0.0001; mean 57.3%) than in reactive marrows (mean 2.5%). FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12). FOXP2 represents the first transcription factor whose expression consistently differentiates normal and abnormal plasma cells and FOXP2 target genes are implicated in MM pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096010     DOI: 10.1111/j.1365-2141.2009.08070.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Authors:  Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

2.  Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

Authors:  K K Wong; D M Gascoyne; P J Brown; E J Soilleux; C Snell; H Chen; L Lyne; C H Lawrie; R D Gascoyne; L M Pedersen; M B Møller; K Pulford; D Murphy; T M Green; A H Banham
Journal:  Leukemia       Date:  2013-07-25       Impact factor: 11.528

3.  Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion.

Authors:  Xia Yan; Huiling Zhou; Tingting Zhang; Pan Xu; Shusen Zhang; Wei Huang; Linlin Yang; Xingxing Gu; Runzhou Ni; Tianyi Zhang
Journal:  Tumour Biol       Date:  2015-07-06

Review 4.  Forkhead box proteins: tuning forks for transcriptional harmony.

Authors:  Eric W-F Lam; Jan J Brosens; Ana R Gomes; Chuay-Yeng Koo
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 5.  Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

6.  MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma.

Authors:  Shuna Yao; Yanyan Liu; Zhihua Yao; Yan Zhao; Haiying Wang; Yuanlin Xu; Jiuyang Zhang; Jing Li; Shujun Yang
Journal:  Oncol Lett       Date:  2018-06-22       Impact factor: 2.967

7.  Foxp-mediated suppression of N-cadherin regulates neuroepithelial character and progenitor maintenance in the CNS.

Authors:  David L Rousso; Caroline Alayne Pearson; Zachary B Gaber; Amaya Miquelajauregui; Shanru Li; Carlos Portera-Cailliau; Edward E Morrisey; Bennett G Novitch
Journal:  Neuron       Date:  2012-04-26       Impact factor: 17.173

8.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

9.  The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest.

Authors:  Duncan M Gascoyne; Hayley Spearman; Linden Lyne; Rathi Puliyadi; Marta Perez-Alcantara; Les Coulton; Simon E Fisher; Peter I Croucher; Alison H Banham
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

10.  FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Authors:  P J Brown; K K Wong; S L Felce; L Lyne; H Spearman; E J Soilleux; L M Pedersen; M B Møller; T M Green; D M Gascoyne; A H Banham
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.